Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease

Mielke, Michelle M. ; Anderson, Matthew ; Ashford, J. Wesson ; Jeromin, Andreas ; Lin, Pei Jung ; Rosen, Allyson ; Tyrone, Jamie ; VandeVrede, Lawren ; Willis, Deanna and Hansson, Oskar LU orcid , et al. (2024) In Alzheimer's and Dementia 20(11). p.8209-8215
Abstract

Diagnosing Alzheimer's disease (AD) poses significant challenges to health care, often resulting in delayed or inadequate patient care. The clinical integration of blood-based biomarkers (BBMs) for AD holds promise in enabling early detection of pathology and timely intervention. However, several critical considerations, such as the lack of consistent guidelines for assessing cognition, limited understanding of BBM test characteristics, insufficient evidence on BBM performance across diverse populations, and the ethical management of test results, must be addressed for widespread clinical implementation of BBMs in the United States. The Global CEO Initiative on Alzheimer's Disease BBM Workgroup convened to address these challenges and... (More)

Diagnosing Alzheimer's disease (AD) poses significant challenges to health care, often resulting in delayed or inadequate patient care. The clinical integration of blood-based biomarkers (BBMs) for AD holds promise in enabling early detection of pathology and timely intervention. However, several critical considerations, such as the lack of consistent guidelines for assessing cognition, limited understanding of BBM test characteristics, insufficient evidence on BBM performance across diverse populations, and the ethical management of test results, must be addressed for widespread clinical implementation of BBMs in the United States. The Global CEO Initiative on Alzheimer's Disease BBM Workgroup convened to address these challenges and provide recommendations that underscore the importance of evidence-based guidelines, improved training for health-care professionals, patient empowerment through informed decision making, and the necessity of community-based studies to understand BBM performance in real-world populations. Multi-stakeholder engagement is essential to implement these recommendations and ensure credible guidance and education are accessible to all stakeholders.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, amyloid, biomarker, blood-based biomarkers, clinical implementation, clinical practice, cognitive impairment, disease-modifying treatment, ethics, patient journey, primary care, secondary care
in
Alzheimer's and Dementia
volume
20
issue
11
pages
7 pages
publisher
Wiley
external identifiers
  • scopus:85205677917
  • pmid:39369283
ISSN
1552-5260
DOI
10.1002/alz.14150
language
English
LU publication?
yes
id
4d680160-3d2a-4c50-8180-1b3207222ba0
date added to LUP
2024-12-20 10:05:33
date last changed
2025-06-07 11:55:28
@article{4d680160-3d2a-4c50-8180-1b3207222ba0,
  abstract     = {{<p>Diagnosing Alzheimer's disease (AD) poses significant challenges to health care, often resulting in delayed or inadequate patient care. The clinical integration of blood-based biomarkers (BBMs) for AD holds promise in enabling early detection of pathology and timely intervention. However, several critical considerations, such as the lack of consistent guidelines for assessing cognition, limited understanding of BBM test characteristics, insufficient evidence on BBM performance across diverse populations, and the ethical management of test results, must be addressed for widespread clinical implementation of BBMs in the United States. The Global CEO Initiative on Alzheimer's Disease BBM Workgroup convened to address these challenges and provide recommendations that underscore the importance of evidence-based guidelines, improved training for health-care professionals, patient empowerment through informed decision making, and the necessity of community-based studies to understand BBM performance in real-world populations. Multi-stakeholder engagement is essential to implement these recommendations and ensure credible guidance and education are accessible to all stakeholders.</p>}},
  author       = {{Mielke, Michelle M. and Anderson, Matthew and Ashford, J. Wesson and Jeromin, Andreas and Lin, Pei Jung and Rosen, Allyson and Tyrone, Jamie and VandeVrede, Lawren and Willis, Deanna and Hansson, Oskar and Khachaturian, Ara S. and Schindler, Suzanne E. and Weiss, Joan and Batrla, Richard and Bozeat, Sasha and Dwyer, John R. and Holzapfel, Drew and Jones, Daryl Rhys and Murray, James F. and Partrick, Katherine A. and Scholler, Emily and Vradenburg, George and Young, Dylan and Braunstein, Joel B. and Burnham, Samantha C. and de Oliveira, Fabricio Ferreira and Hu, Yan Helen and Mattke, Soeren and Merali, Zul and Monane, Mark and Sabbagh, Marwan Noel and Shobin, Eli and Weiner, Michael W. and Udeh-Momoh, Chinedu T.}},
  issn         = {{1552-5260}},
  keywords     = {{Alzheimer's disease; amyloid; biomarker; blood-based biomarkers; clinical implementation; clinical practice; cognitive impairment; disease-modifying treatment; ethics; patient journey; primary care; secondary care}},
  language     = {{eng}},
  number       = {{11}},
  pages        = {{8209--8215}},
  publisher    = {{Wiley}},
  series       = {{Alzheimer's and Dementia}},
  title        = {{Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease}},
  url          = {{http://dx.doi.org/10.1002/alz.14150}},
  doi          = {{10.1002/alz.14150}},
  volume       = {{20}},
  year         = {{2024}},
}